Erie Times-News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...
clinicaladvisor.com

RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations. The Food and Drug Administration (FDA) has expanded the approval of ...
Seeking Alpha

European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of LRTD ...
Nasdaq

Pfizer: ABRYSVO Now Approved In The EU To Prevent RSV In Adults Aged 18 And Older

(RTTNews) - Pfizer (PFE) announced the European Commission has issued a decision amending the marketing authorization for ABRYSVO, the company's bivalent respiratory syncytial virus prefusion F ...
The Indianapolis Star

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...